M
Manuel Carcao
Researcher at University of Toronto
Publications - 179
Citations - 5011
Manuel Carcao is an academic researcher from University of Toronto. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 35, co-authored 158 publications receiving 3880 citations. Previous affiliations of Manuel Carcao include Hospital for Sick Children & McMaster University.
Papers
More filters
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw,H. Marijke van den Berg,Krista Fischer,Guenter Auerswald,Manuel Carcao,Elizabeth Chalmers,Hervé Chambost,Karin Kurnik,Ri Liesner,Pia Petrini,Helen Platokouki,Carmen Altisent,Johannes Oldenburg,Beatrice Nolan,Rosario Perez Garrido,M Elisa Mancuso,Anne Rafowicz,Michael Williams,Niels Clausen,Rutger A. Middelburg,Rolf Ljung,Johanna G. van der Bom +21 more
TL;DR: It is suggested that in previously untreated patients with severe hemophilia A, high-dosed intensive FVIII treatment increases inhibitor risk and prophylactic FV III treatment decreases inhibitor risk, especially in patients with low-risk F8 mutations.
Journal ArticleDOI
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
Anjali Sharathkumar,David Lillicrap,Victor S. Blanchette,M A Kern,Jayne Leggo,A. M. Stain,L. Brooker,Manuel Carcao +7 more
TL;DR: The incidence of inhibitors in the MHA population was 7.4%.
Journal ArticleDOI
The Platelet Function Analyzer (PFA‐100®): a novel in‐vitro system for evaluation of primary haemostasis in children
Manuel Carcao,Victor S. Blanchette,J.A. Dean,L He,M A Kern,A. M. Stain,Cathy Sparling,Derek Stephens,G Ryan,John Freedman,Margaret L. Rand +10 more
TL;DR: The PFA‐100 system was found to be potentially useful in screening for von Willebrand disease in children and normal ranges for CTs in healthy children, adults and neonates were established.
Journal ArticleDOI
von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
J.A. Dean,Victor S. Blanchette,Manuel Carcao,A. M. Stain,Cathy Sparling,J. Siekmann,P. L. Turecek,David Lillicrap,Margaret L. Rand +8 more
TL;DR: Using the ISTH consensus guidelines for type 1 VWD definition, significantly fewer patients were diagnosed with definite type 1 disease as compared to the "in house" Hospital for Sick Children (HSC) criteria (4 vs. 31).